Some authors have suggested that tyrosine kinase inhibitors could cause serosal inflammation (pleural and pericardial effusions) by their ability to inhibit multiple targets as Platelet Derived Growth Factor Receptor β (PDGFR-β) and Src family tyrosine kinases, which are involved in the maintenance of interstitial fluid tissue pressure and endothelial permeability (Kelly et al., 2009). The gene discussed is PDGFRB; the disease is pericardial effusion.